Lixte Biotechnology Shares Are Trading Higher After the Company Received a USPTO Notice of Allowance for a Patent Combing LB-100 With Cancer Immunotherapies.
Lixte Biotechnology Shares Are Trading Higher After the Company Received a USPTO Notice of Allowance for a Patent Combing LB-100 With Cancer Immunotherapies.
Lixte生物科技股價上漲，因公司收到美國專利商標局允許通知，該專利將Lb-100與癌症免疫療法結合。
Lixte Biotechnology Shares Are Trading Higher After the Company Received a USPTO Notice of Allowance for a Patent Combing LB-100 With Cancer Immunotherapies.
lixte biotechnology股價上漲，因爲該公司收到美國專利商標局關於將Lb-100與癌症免疫療法相結合的專利通知。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間